Neuromuscular Pathology Overview

Principles

Definition

Neuromuscular pathology is a specialized field of study within medicine and neuroscience. It focuses on the investigation, diagnosis, and understanding of diseases affecting the peripheral nerves, muscles, and the neuromuscular junction, encompassing their etiology, pathophysiology, and clinical manifestations.

Ontological type

Core Disease Categories

Diagnostic Techniques

Pathophysiological Mechanisms

Key developments

Key Figures

Electrophysiology and Pharmacology era

John V. Basmajian [1] was associated with the University of Toronto [3] and Queen's University [4] during the Electrophysiology and Pharmacology era. Basmajian [1] advanced functional neurophysiology through electromyography, as evidenced by the 1962 EMG paper [5], which highlighted transmission, reinnervation, and motor-unit plasticity and helped shape diagnostic and therapeutic approaches in this era. W. King Engel [2] has no listed institutional affiliations in this era. Engel [2] contributed to clinical neuromuscular pathology through the nemaline myopathy paper [6], which clarified the clinicopathologic features of nemaline myopathy and underscored the role of electrophysiology in characterizing congenital myopathies during this era.

Structural-Molecular Pathology era

Kevin P. Campbell [1] is associated with Johns Hopkins University [3] and Baylor College of Medicine [4] during this era. His key contributions include Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle [7], Dystrophin-associated proteins are greatly reduced in skeletal muscle from mdx mice [8], and Dystrophin-related protein is localized to neuromuscular junctions of adult skeletal muscle [9], which collectively advanced the structural-molecular understanding of neuromuscular disease in this era. H. Lee Sweeney [2] was affiliated with Harvard University [5] and The University of Texas Southwestern Medical Center [6] during this era. His 1993 paper Dystrophin protects the sarcolemma from stresses developed during muscle contraction [10] established that dystrophin protects the sarcolemma from contraction-induced stresses and highlighted membrane stability as a central mechanism shaping diagnostic and mechanistic interpretations in this era.

Genetics-Driven Therapeutics era

Nigel G. Laing [1] is a key figure in neuromuscular pathology during the Genetics-Driven Therapeutics era, with affiliations spanning Northwestern University [3] and University College London [4]. His work, including the discovery of mutations in the skeletal muscle α-actin gene in actin myopathy and nemaline myopathy [7], mutations in TPM3 associated with autosomal dominant nemaline myopathy [8], and loss‑of‑function mutations in SCN4A causing severe foetal hypokinesia or 'classical' congenital myopathy [9], established genotype–phenotype links that propelled genetic diagnostics and targeted therapeutic strategies in this era. Richard S. Finkel [2], with affiliations at Harvard University [5] and Stanford University [6], has been a leading voice in translating genetic discoveries into therapies during this era. His notable contribution includes the treatment of infantile-onset spinal muscular atrophy with nusinersen, a phase 2 open-label dose-escalation study published in 2016 [10], illustrating the promise of antisense oligonucleotide therapies and shaping subsequent precision clinical trials in neuromuscular diseases.